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Abstract
Klotho (KL) is a putative tumor suppressor gene in breast and pancreatic cancers located at
chromosome 13q12. A functional sequence variant of Klotho (KL-VS) was previously reported to
modify breast cancer risk in Jewish BRCA1 mutation carriers. The effect of this variant on breast
and ovarian cancer risks in non-Jewish BRCA1/BRCA2 mutation carriers has not been reported.
The KL-VS variant was genotyped in women of European ancestry carrying a BRCA mutation:
5,741 BRCA1 mutation carriers (2,997 with breast cancer, 705 with ovarian cancer, and 2,039
cancer free women) and 3,339 BRCA2 mutation carriers (1,846 with breast cancer, 207 with
ovarian cancer, and 1,286 cancer free women) from 16 centers. Genotyping was accomplished
using TaqMan® allelic discrimination or matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry. Data were analyzed within a retrospective cohort approach, stratified by
country of origin and Ashkenazi Jewish origin. The per-allele hazard ratio (HR) for breast cancer
was 1.02 (95% CI 0.93–1.12, P = 0.66) for BRCA1 mutation carriers and 0.92 (95% CI 0.82–1.04,
P = 0.17) for BRCA2 mutation carriers. Results remained unaltered when analysis excluded
prevalent breast cancer cases. Similarly, the per-allele HR for ovarian cancer was 1.01 (95% CI
0.84–1.20, P = 0.95) for BRCA1 mutation carriers and 0.9 (95% CI 0.66–1.22, P = 0.45) for
BRCA2 mutation carriers. The risk did not change when carriers of the 6174delT mutation were
excluded. There was a lack of association of the KL-VS Klotho variant with either breast or
ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Keywords
Breast cancer; Ovarian cancer-Klotho; BRCA; Modifier gene
Introduction
The Klotho (KL) gene (MIM # 604824) encodes a 1,014 amino acid transmembrane protein
[1]. The Klotho protein has pleiotropic activities, including potent inhibition of the insulin
receptor (IR) and the IGF-1 receptor (IGF-1R) [2]. This pathway plays a prominent role in
breast cancer pathogenesis [3, 4] and specifically in BRCA1–BRCA2-associated breast
cancers [5, 6] and epithelial ovarian cancer [7]. These functional activities, taken together
with the in vitro evidence of its tumor suppressor activity in breast cancer cell lines and
altered expression somatically in breast cancer tissues [8], combined with the chromosomal
location of the gene at 13q12, a frequent site of allelic loss in breast and ovarian tumors [9],
make KL a putative tumor suppressor gene in breast and ovarian cancer. Since the lifetime
risk for developing these tumor types is substantially increased in women who carry
germline mutations in BRCA1 or BRCA2 [10, 11], it seemed plausible that KL could affect
cancer penetrance in BRCA1 and/or BRCA2 mutation carriers. Indeed, we have previously
shown that loss of function sequence variants in the Klotho gene [amino acid substitutions
F352V (rs9536314) and C370S (rs9527025) both in linkage disequilibrium—coined KL-
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VS] that can be evaluated by genotyping the rs9536314 SNP are associated with an altered
breast cancer risk in Jewish Ashkenazi BRCA1 mutation carriers [12]. As the penetrance of
mutated BRCA1 and BRCA2 alleles may in part be determined by the location and the type
of mutation, and by other genetic factors, at times ethnically restricted, and since the
mutational spectrum in Ashkenazi Jews in BRCA1 is limited [13, 14], this study aimed to
evaluate the putative modifier effect of the KL-VS sequence variants on mutant BRCA1 and
BRCA2 allele penetrance in a larger cohort of ethnically diverse mutation carriers.
Methods
Study participants—recruitment and data collection
All study participants were women, aged 18 years or above, who carried a deleterious
germline mutation in either BRCA1 or BRCA2. Study participant genotype and phenotype
data were submitted from 16 centers participating in the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA) [15]. The recruitment strategy and the type of clinical,
demographic, and phenotypic data collected from each participant, as well as the means used
to ensure that there are no overlaps and no duplicate genotyping, have previously been
reported [15, 16]. All study participants took part in research studies at the parent
institutions under ethically approved protocols as previously detailed [15, 16].
Genetic analysis
All participating centers genotyped the KL-VS variant (rs9536314) using matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) [16], or
TaqMan® allelic discrimination with limited sequencing, as previously described [12].
Genotyping quality control procedures were carried out as reported elsewhere
(http://www.srl.cam.ac.uk/consortia/cimba/eligibility/eligibility.html).
Statistical analysis
Data were analyzed within a retrospective likelihood approach [17], assuming a proportional
hazards model for the effect of the genotype on cancer incidence. For the breast cancer
analysis, carriers were censored at the age of the first of the following events: breast cancer
diagnosis, ovarian cancer diagnosis, bilateral prophylactic mastectomy, or age at last
observation. Only those censored at a breast cancer diagnosis were assumed to be affected.
To evaluate the association with ovarian cancer risk, data were analyzed within a competing
risks model framework, which evaluates the associations with breast and ovarian cancer risk
simultaneously [18]. For this analysis, mutation carriers were followed up to the age of the
first breast or ovarian cancer diagnosis and were considered to have developed the
corresponding disease. Individuals were censored for breast cancer at the age of bilateral
prophylactic mastectomy and for ovarian cancer at the age of bilateral oophorectomy and
were assumed to be unaffected for the corresponding disease. The remaining individuals
were censored at the age at last observation and were assumed to be unaffected for both
diseases. For all models, the effect of each SNP was modeled either as a per-allele hazard
ratio (HR) (multiplicative model) or as separate HRs for heterozygotes and homozygotes,
and these were estimated on the log scale (i.e., βi). Analyses were carried out using the
pedigree analysis software MENDEL [19]. A robust variance-estimation approach was used
to allow for the non-independence among related carriers [20]. Analyses were stratified by
country of residence and used calendar-year- and cohort-specific cancer incidences for
BRCA1 and BRCA2 [21]. Because of the previously reported linkage disequilibrium
between the KL-VS variant and BRCA2 6174delT mutation [12], the US American BRCA2
carriers, who contributed the majority of the 6174delT mutation carriers, were further
stratified according to whether they carried this particular mutation or not.
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Results
A total of 9,080 mutation carriers (5,741 BRCA1 and 3,339 BRCA2 mutation carriers) from
16 centers were included in the current analysis (Table 1, Supplementary Table 1). In the
breast cancer analysis there were 4,870 subjects with breast cancer (3,020 BRCA1 mutation
carriers, 1,850 BRCA2 mutation carriers), and 4,210 unaffected carriers (2,721 BRCA1
carriers, 1,489 BRCA2 carriers) (Tables 1, 2). The genotype frequencies and estimated HRs
by mutation and disease status for breast and ovarian cancer are shown in Tables 2, 3, and 4.
There was no evidence of association between breast cancer risk and the KL-VS genotype
for either BRCA1 or BRCA2 mutation carriers (per-allele HR = 1.02, 95% CI 0.93–1.12, P
= 0.66 and 0.92, 95% CI 0.82–1.04, P = 0.17 for BRCA1 and BRCA2, respectively). There
was no evidence of heterogeneity in the HRs across studies: p-het = 0.91 for BRCA1 and p-
het = 0.78 for BRCA2 (Fig. 1a, b). There was also no evidence of association of the Klotho
sequence variant with ovarian cancer risk for BRCA1 mutation carriers (per-allele HR =
1.01, 95% CI 0.84–1.20, P = 0.95) or BRCA2 mutation carriers (per-allele HR = 0.90, 95%
CI 0.66–1.22, P = 0.49) (Table 4). The results were unchanged when long-term cancer
survivors (prevalent cases) were excluded from the analyses, or when carriers of the
6174delT mutation were excluded. Furthermore, the KL-VS variant was not significantly
associated with breast cancer risk in an analysis of self-reported Ashkenazi Jewish
participants (HR = 1.22, 95% CI 0.91–1.64, P = 0.18 for 374 BRCA1 mutation carriers and
HR = 0.97, 95% CI 0.56–1.69, P = 0.93 for 209 BRCA2 mutation carriers).
Discussion
In this study, functional KL gene variants had no discernable effect on either breast or
ovarian cancer risk in a large group of ethnically diverse BRCA1 and BRCA2 mutation
carriers. These findings are in contrast with our previous report which showed that in Jewish
BRCA1 mutation carriers there was an association of the same sequence variant on breast
cancer risk [12]. The estimated HRs based on the complete sample as well as the restricted
sample of Ashkenazi Jewish mutation carriers was considerably smaller than the relative
risk reported previously. Several reasons could account for the lack of replication in this
study: the number of self-reported Ashkenazi Jewish individuals in this study was relatively
small (BRCA1 n = 374, BRCA2 n = 209). Therefore, if the association is restricted to
Ashkenazi Jewish mutation carriers only, the present analysis may be under-powered.
Alternatively, given the sample size of this study, the original finding may have been a false
positive. It is well established that the mutation location and mutation type affect cancer risk
in BRCA1 and BRCA2 mutation carriers [22, 23]. As the mutational spectrum locations and
types in the present analysis was more diverse than in the Ashkenazi population, it is also
possible that these inconsistencies in the results between this study and the previous one
may relate to the effect of the Klotho variant on the specific Ashkenazi mutations based on
their location and effect on protein.
Although this particular polymorphism did not show any effect on breast/ovarian cancer risk
in BRCA1/BRCA2 mutation carriers, Klotho gene may still modify these risks by another
sequence alteration that may be in linkage equilibrium in the Ashkenazi Jewish population
or by other variants not or only in weak linkage disequilibrium with the current
polymorphism, by epigenetic alterations in gene expression (e.g., methylation, miRNA
effects) or in combination and interaction with other polymorphisms that in concert have an
overall effect on cancer risk.
In conclusion, the KL-VS sequence variant in the Klotho gene has no major effect on breast
or ovarian cancer risk in genetically susceptible, ethnically diverse individuals who carry
either a deleterious BRCA1 or a BRCA2 mutation. However, the effect of this gene and its
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putative involvement in penetrance of mutant BRCA1 or BRCA2 alleles by other genetic or
epigenetic mechanisms cannot be ruled out, especially in Ashkenazi Jews.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
a Per-allele stratum-specific HRs for breast cancer risk in BRCA1 carriers and b Per-allele
stratum-specific HRs for breast cancer risk in BRCA2 carriers
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Table 1
Summary characteristics for the 9080 eligible BRCA1 and BRCA2 mutation carriers used in the analysis
Characteristic BRCA1 BRCA2
Unaffected Breast Cancer Unaffected Breast Cancer
Number 2,721 3,020 1,489 1,850
Person-years follow-up 116,795 122,809 66,559 81,486
Median age at censure (IQR) 42 (33–51) 39 (34–46) 43 (35–53) 43 (37–50)
Age at censure, N (%)
  <30 567 (20.8) 392 (13.0) 288 (19.3) 169 (9.1)
  30–39 707 (26.0) 1205 (39.9) 359 (24.1) 546 (29.5)
  40–49 727 (26.7) 968 (32.1) 391 (26.3) 678 (36.7)
  50–59 463 (17.0) 350 (11.6) 242 (16.3) 324 (17.5)
  60–69 178 (6.5) 89 (3.0) 137 (9.2) 100 (5.4)
  70+ 79 (2.9) 16 (0.5) 72 (4.8) 33 (1.8)
Year of birth, N (%)
  <1920 9 (0.3) 13 (0.4) 11 (0.7) 23 (1.2)
  1920–1929 62 (2.3) 105 (3.5) 46 (3.0) 85 (4.6)
  1930–1939 196 (7.2) 279 (9.2) 115 (7.0) 214 (11.6)
  1940–1949 413 (15.2) 651 (21.6) 206 (13.8) 420 (22.7)
  1950–1959 603 (22.2) 890 (29.5) 315 (20.8) 584 (31.6)
  1960–1969 755 (27.8) 794 (26.3) 429 (27.2) 458 (23.1)
  1970+ 683 (25.1) 288 (9.5) 367 (27.6) 96 (5.2)
Ethnicity, N (%)
Ashkenazi Jewish 172 (6.3) 202 (6.7) 105 (7.1) 104 (5.6)
Not Ashkenazi Jewish 2,549 (93.7) 2,818 (93.3) 1,384 (92.9) 1,746 (94.4)
IQR interquartile range Carriers of European or Ashkenazi Jewish ancestry only
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